<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: <z:hpo ids='HP_0001427'>Mitochondrial</z:hpo> <z:chebi fb="1" ids="17478">aldehyde</z:chebi> dehydrogenase (ALDH2) displays some promise in the protection against <z:e sem="disease" ids="C0007222" disease_type="Disease or Syndrome" abbrv="CVD">cardiovascular diseases</z:e> although its role in <z:mp ids='MP_0002055'>diabetes</z:mp> has not been elucidated </plain></SENT>
<SENT sid="1" pm="."><plain>METHODS: This study was designed to evaluate the impact of ALDH2 on <z:chebi fb="1" ids="9288">streptozotocin</z:chebi>-induced diabetic <z:hpo ids='HP_0001638'>cardiomyopathy</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>Friendly virus B(FVB) and ALDH2 transgenic mice were treated with <z:chebi fb="1" ids="9288">streptozotocin</z:chebi> (intraperitoneal injection of 200 mg/kg) to induce <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="3" pm="."><plain>RESULTS: Echocardiographic evaluation revealed reduced fractional shortening, increased end-systolic and -diastolic diameter, and decreased wall thickness in <z:chebi fb="1" ids="9288">streptozotocin</z:chebi>-treated FVB mice </plain></SENT>
<SENT sid="4" pm="."><plain><z:chebi fb="1" ids="9288">Streptozotocin</z:chebi> led to a <z:mp ids='MP_0010379'>reduced respiratory exchange ratio</z:mp>; myocardial <z:mpath ids='MPATH_3'>apoptosis</z:mpath> and <z:hpo ids='HP_0001427'>mitochondrial</z:hpo> damage; cardiomyocyte contractile and intracellular <z:chebi fb="0" ids="29108">Ca2+</z:chebi> defects, including depressed peak shortening and maximal velocity of shortening and relengthening; prolonged duration of shortening and relengthening; and dampened intracellular <z:chebi fb="0" ids="29108">Ca2+</z:chebi> rise and clearance </plain></SENT>
<SENT sid="5" pm="."><plain>Western blot analysis revealed disrupted phosphorylation of Akt, <z:chebi fb="15" ids="28087">glycogen</z:chebi> synthase kinase-3β and Foxo3a (but not mammalian target of <z:chebi fb="0" ids="9168">rapamycin</z:chebi>), elevated PTEN phosphorylation and downregulated expression of <z:hpo ids='HP_0001427'>mitochondrial</z:hpo> proteins, peroxisome proliferator-activated receptor γ coactivator 1α and UCP-2 </plain></SENT>
<SENT sid="6" pm="."><plain>Intriguingly, ALDH2 attenuated or ablated <z:chebi fb="1" ids="9288">streptozotocin</z:chebi>-induced echocardiographic, <z:hpo ids='HP_0001427'>mitochondrial</z:hpo>, apoptotic and myocardial contractile and intracellular <z:chebi fb="0" ids="29108">Ca2+</z:chebi> anomalies as well as changes in the phosphorylation of Akt, <z:chebi fb="15" ids="28087">glycogen</z:chebi> synthase kinase-3β, Foxo3a and phosphatase and tensin homologue on chromosome ten, despite persistent <z:hpo ids='HP_0003074'>hyperglycemia</z:hpo> and a low respiratory exchange ratio </plain></SENT>
<SENT sid="7" pm="."><plain>In vitro data revealed that the ALDH2 activator Alda-1 and <z:chebi fb="15" ids="28087">glycogen</z:chebi> synthase kinase-3β inhibition protected against high <z:chebi fb="105" ids="17234">glucose</z:chebi>-induced <z:hpo ids='HP_0001427'>mitochondrial</z:hpo> and mechanical anomalies, the effect of which was cancelled by <z:hpo ids='HP_0001427'>mitochondrial</z:hpo> uncoupling </plain></SENT>
<SENT sid="8" pm="."><plain>CONCLUSIONS: In summary, our data revealed that ALDH2 acted against <z:mp ids='MP_0002055'>diabetes</z:mp>-induced cardiac contractile and intracellular <z:chebi fb="0" ids="29108">Ca2+</z:chebi> dysregulation, possibly through regulation of <z:mpath ids='MPATH_3'>apoptosis</z:mpath>, <z:chebi fb="15" ids="28087">glycogen</z:chebi> synthase kinase-3β activation and <z:hpo ids='HP_0001427'>mitochondrial</z:hpo> function independent of the global metabolic profile </plain></SENT>
</text></document>